



A Partnership Solution by  INMEDIATA and  prognosis

TRANSPARENCY AND DISCLOSURE AGREEMENT - ONC CERTIFICATION FOR HEALTHCARE IT

*Version No: Denali 3.1 B2
Dated 4/29/2025*

TRANSPARENCY AND DISCLOSURE AGREEMENT

This Health IT Module is compliant with the ONC Certification Criteria for Health IT and has been certified by an ONC-ACB in accordance with the applicable certification criteria adopted by the Secretary of Health and Human Services. This certification does not represent an endorsement by the U.S. Department of Health and Human Services.

- a. **Vendor Name** - Inmediata Health Group, LLC.
- b. **Date of Certification** - 4/23/2021
- c. **Product Name and Version** - SecureEMR+ Version-Delani 3.1
- d. **Unique Certification Number or other specific product identification**
-15.04.04.2769.Secu.03.01.1.210423

e. **ONC Certified Healthcare IT Criteria:**

SecureEMR+ 3.1 is certified by Drummond Group for the following ONC certification HIT criteria adopted by the Secretary of Health and Human Services:

Criterion # and Description	Test Status
§ 170.315(a)(1) CPOE-Medication	Gap Certification Eligible
§ 170.315(a)(2) CPOE—Laboratory	Gap Certification Eligible
§ 170.315(a)(3) CPOE-Imaging	Gap Certification Eligible
§ 170.315(a)(4) Drug-Drug, Drug-Allergy Interaction Checks	Gap Certification Eligible
§ 170.315(a)(5) Demographics	Pass
Removed § 170.315(a)(6) Problem List	Pass (Criteria Removed from Program)

Removed § 170.315(a)(7) Medication List	Pass (Criteria Removed from Program)
Removed § 170.315(a)(8) Medication Allergy List	Pass (Criteria Removed from Program)
Removed § 170.315(a)(9) Clinical Decision Support	Pass (Criteria Removed from Program)
Removed § 170.315(a)(10) Drug Formulary Checks	Pass (Criteria Removed from Program)
Removed § 170.315(a)(11) Smoking Status	Pass (Criteria Removed from Program)
§ 170.315(a)(12) Family Health History	Pass
Removed § 170.315(a)(13) Patient-Specific Education Resources	Pass (Criteria Removed from Program)
§ 170.315(a)(14) Implantable Device List	Pass
§ 170.315(a)(15) Social, Psychological, and Behavioral Data	Pass
§ 170.315(b)(1) Transitions of Care	Pass
§ 170.315(b)(2) Clinical Information Reconciliation and Incorporation	Pass
§ 170.315(b)(3) Electronic Prescribing	Pass

Removed § 170.315(b)(4) Common Clinical Data Set summary record – create	Pass (Criteria Removed from Program)
Removed § 170.315(b)(5) Common Clinical Data Set summary record – receive	Pass (Criteria Removed from Program)
Removed § 170.315(b)(6) Data Portability	Pass (Criteria Removed from Program)
§170.315(b)(10) Electronic Health Information export	Pass
§170.315(b)(11) Decision support interventions	Pass
§ 170.315(c)(1) Clinical Quality Measures – record and export	Pass
§ 170.315(c)(2) Clinical Quality Measures – import and calculate	Pass
§ 170.315(c)(3) Clinical Quality Measures – - record	Pass
§ 170.315(c)(4) Clinical Quality Measures – filter	Pass
§ 170.315(d)(1) Authentication, Access Control, and Authorization	Gap Certification Eligible
§ 170.315(d)(2) Auditable Events and Tamper-Resistance	Pass
§ 170.315(d)(3) Audit Report(s)	Pass
§ 170.315(d)(4) Amendments	Gap Certification Eligible

§ 170.315(d)(5) Automatic Log-Off	Gap Certification Eligible
§ 170.315(d)(6) Emergency Access	Gap Certification Eligible
§ 170.315(d)(7) End-User Device Encryption	Gap Certification Eligible
§ 170.315(d)(8) Integrity	Pass
§ 170.315(d)(9) Trusted connection	Pass
§ 170.315 (d)(12) Encrypt Authentication Credentials (Pass
§ 170.315 (d)(13) Multi-Factor Authentication	Pass
§ 170.315(e)(1) View, Download, and Transmit to 3rd Party	Pass
Removed § 170.315(e)(2) Secure Messaging	Pass (Criteria Removed from Program)
§ 170.315 (e)(3) Patient Health Information Capture	Pass
§ 170.315(f)(1) Transmission to Immunization Registries	Pass
§ 170.315(f)(2) Transmission to Public Health Agencies - Syndromic Surveillance	Pass
§ 170.315 (f)(5) Transmission to Public Health Agencies - Electronic Case Reporting	Pass

§ 170.315(f)(7) Transmit to Public Health Agencies – health care Surveys	Pass
§ 170.315(g)(2) Automated Measure Calculation	Pass
§ 170.315(g)(3) Safety-Enhanced Design	Pass
§ 170.315(g)(4) Quality Management System	Pass
§ 170.315(g)(5) Accessibility-Centered Design	Pass
§ 170.315(g)(6) Consolidated CDA Creation Performance	Pass
§ 170.315 (g)(7) Application Access - Patient Selection	Pass
§ 170.315 (g)(9) Application Access - All Data Request	Pass
§ 170.315 (g)(10) Standardized API for Patient and Population Services	Pass
§ 170.315 (h)(1) Direct Project	Pass

f. Clinical Quality Measures:

eCQM ID	eCQM Title
CMS2v7	Preventive Care and Screening: Screening for Depression and Follow-Up Plan
CMS22v6	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
CMS50v6	Closing the Referral Loop: Receipt of Specialist Report
CMS52v6	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis
CMS56v6	Functional Status Assessment for Total Hip Replacement
CMS65v7	Hypertension: Improvement in Blood Pressure
CMS66v6	Functional Status Assessment for Total Knee Replacement
CMS68v7	Documentation of Current Medications in the Medical Record
CMS69v5	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
CMS74v7	Primary Caries Prevention Intervention as Offered by Dentists
CMS75v6	Children Who Have Dental Decay or Cavities
CMS82v4	Maternal Depression Screening
CMS90v7	Functional Status Assessments for Heart Failure
CMS117v6	Childhood Immunization Status
CMS122v5	Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%)
CMS123v5	Diabetes: Foot Exam
CMS124v5	Cervical Cancer Screening
CMS125v5	Breast Cancer Screening
CMS126v5	Use of Appropriate Medications for Asthma
CMS127v5	Pneumococcal Vaccination Status for Older Adults
CMS128v6	Anti-depressant Medication Management
CMS129v7	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
CMS130v5	Colorectal Cancer Screening
CMS131v5	Diabetes: Eye Exam

CMS132v6	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures
CMS133v6	Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
eCQM ID	eCQM Title
CMS134v5	Diabetes: Medical Attention for Nephropathy
CMS135v6	Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
CMS136v7	Follow-Up Care for Children Prescribed ADHD Medication (ADD)
CMS137v6	Initiation and Engagement of Substance Use Disorder Treatment
CMS138v5	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
CMS139v5	Falls: Screening for Future Fall Risk
CMS142v5	Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
CMS143v5	Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation
CMS144v5	Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
CMS145v6	Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF) less than or equal to 40%
CMS146v5	Appropriate Testing for Pharyngitis
CMS147v6	Preventive Care and Screening: Influenza Immunization
CMS148v5	Hemoglobin A1c Test for Pediatric Patients
CMS149v6	Dementia: Cognitive Assessment
CMS153v6	Chlamydia Screening in Women
CMS154v5	Appropriate Treatment for Upper Respiratory Infection (URI)
CMS155v5	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents
CMS156v5	Use of High-Risk Medications in Older Adults
CMS157v6	Oncology: Medical and Radiation - Pain Intensity Quantified
CMS158v6	Pregnant women that had HBsAg testing

CMS159v6	Depression Remission at Twelve Months
CMS160v6	Depression Utilization of the PHQ-9 Tool
CMS161v6	Adult Major Depressive Disorder (MDD): Suicide Risk Assessment
CMS163v5	Diabetes: Low Density Lipoprotein (LDL) Management
eCQM ID	eCQM Title
CMS164v5	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet
CMS165v5	Controlling High Blood Pressure
CMS166v6	Use of Imaging Studies for Low Back Pain
CMS167v6	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
CMS169v6	Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use
CMS177v6	Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment
CMS182v6	Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
CMS249v4	Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic Fracture
CMS347v5	Statin Therapy for the Prevention and Treatment of Cardiovascular Disease
CMS349v4	Compare Versions of: "HIV Screening"
CMS645v1	Bone density evaluation for patients with prostate cancer and receiving androgen deprivation therapy
CMS646v2	Intravesical Bacillus-Calmette-Guerin for non-muscle invasive bladder cancer
CMS771v3	Urinary Symptom Score Change 6-12 Months After Diagnosis of Benign Prostatic Hyperplasia

g. Additional Software:

Self-attested Additional Software Used in Testing:

Product Name	Product Version	Supplier	Criteria this product supports
--------------	-----------------	----------	--------------------------------

MedKnowledge	October 2022	First Databank Drug Database	<p>§ 170.315(a)(1)</p> <p>§ 170.315(a)(4)</p> <p>§ 170.315(a)(7)</p> <p>§ 170.315(a)(8)</p> <p>§ 170.315(a)(10)</p> <p>§ 170.315(b)(1)</p> <p>§ 170.315(b)(2)</p> <p>§ 170.315(b)(3)</p> <p>§ 170.315(b)(4)</p> <p>§ 170.315(b)(5)</p> <p>§ 170.315(b)(6)</p> <p>§ 170.315(c)(1)</p> <p>§ 170.315(c)(2)</p> <p>§ 170.315(c)(3)</p> <p>§ 170.315(c)(4)</p> <p>§ 170.315(e)(1)</p> <p>§ 170.315(f)(5)</p> <p>§ 170.315(f)(7)</p> <p>§ 170.315(g)(2)</p> <p>§ 170.315(g)(6)</p> <p>§ 170.315(g)(7)</p> <p>§ 170.315(g)(8)</p>
--------------	--------------	------------------------------	--

			§ 170.315(g)(9) § 170.315(g)(10)
Medline Plus	NA	National Institute of Health	§ 170.315(a)(9) § 170.315(a)(13)
Problem (IT) Terminology	2022	Intelligent Medical Objects	§ 170.315(a)(6) § 170.315(a)(9) §170.315(a)(11) §170.315(a)(12) §170.315(a)(13) §170.315(a)(14) §170.315(a)(15) § 170.315(b)(1) § 170.315(b)(2) § 170.315(b)(3) § 170.315(b)(4) § 170.315(b)(5) § 170.315(b)(6) § 170.315(c)(1) § 170.315(c)(2) § 170.315(c)(3) § 170.315(c)(4) § 170.315(e)(1)

			§ 170.315(f)(5) § 170.315(f)(7) § 170.315(g)(2) § 170.315(g)(6) § 170.315(g)(7) § 170.315(g)(8) § 170.315(g)(9) § 170.315(g)(10)
Procedure (IT) Terminology	2022 Procedure IT FULL	Intelligent Medical Objects	§ 170.315(a)(6) § 170.315(a)(9) §170.315(a)(11) §170.315(a)(12) §170.315(a)(13) §170.315(a)(14) §170.315(a)(15) § 170.315(b)(1) § 170.315(b)(2) § 170.315(b)(3) § 170.315(b)(4) § 170.315(b)(5) § 170.315(b)(6) § 170.315(c)(1)

			§ 170.315(c)(2)
			§ 170.315(c)(3)
			§ 170.315(c)(4)
			§ 170.315(e)(1)
			§ 170.315(f)(5)
			§ 170.315(f)(7)
			§ 170.315(g)(2)
			§ 170.315(g)(6)
			§ 170.315(g)(7)
			§ 170.315(g)(8)
			§ 170.315(g)(9)
			§ 170.315(g)(10)

Disclosure of Additional types of costs where applicable:

In order to maintain ongoing and uninterrupted access to certified capabilities, the annual support and maintenance costs may apply, based on each individual customer's contractual agreement with Bizmatics Inc.

Disclosure of any limitations where applicable:

None